Improving Shingrix Vaccination Among US Veterans Receiving Immunosuppression

Not Applicable

• Conditions: Immunosuppresion
• Interventions: Other: Access to Shingrix dashboard

• Registration Number: NCT06596148
• Lead Sponsor: University of California, San Francisco

Brief Summary

The goal of this wait-list control trial is to learn if having access to a new dashboard displaying information about immunosuppressed Veterans missing vaccinations for Shingrix can improve Shingrix vaccination rates at VA facilities.

The main question\[s\] it aims to answer is: Will vaccination rates improve more rapidly for facilities with access to the dashboard compare to facilities without access? VA facility personnel will be granted access to the dashboard and outcomes (vaccination rates) will be measured using electronic health record data.

Detailed Description

Assignment of the intervention will occur at the facility level. Outcomes (vaccination) will be assessed for patients cared for at each facility.

Study Timeline

• Study First Submitted: 2024-09-09
• Study First Submitted QC: 2024-09-12
• Study Start: 2024-09-16
• Study First Posted: 2024-09-19
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-02
• Last Update Posted: 2025-04-06
• Primary Completion: 2026-03
• Study Completion: 2026-06-30

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 130

Inclusion Criteria

• In order to be included in the study, clinicians need to work at a VHA facility and have access to the electronic health record.

Exclusion Criteria

• None.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Early dashboard access	Access to Shingrix dashboard	The early dashboard access arm will receive access to the Shingrix dashboard as soon as the study begins.
Wait list control arm	Access to Shingrix dashboard	The wait list control arm will receive no intervention for 6-9 months; after this period, this arm will also receive access to the Shingrix dashboard.

Primary Outcome Measures

Name	Time	Method
Percentage of patients with at least 1 Shingrix vaccine documented, by facility	From enrollment until end of follow up at 18 months.	Percentage of patients with at least 1 Shingrix vaccinations documented, by facility

Secondary Outcome Measures

Name	Time	Method
Percentage of patients with at least 2 Shingrix vaccinations documented, by facility	From enrollment until end of follow up at 18 months.	Percentage of patients with at least 2 Shingrix vaccinations documented, by facility

Trial Locations

Locations (1)

San Francisco VA; 🇺🇸 San Francisco, California, United States